









Markets
/
Stocks
/
nasdaq-imrn
/

Immuron Ltd

IMRN

1.640USD

-0.020-1.20%

Close 11/07, 16:00（ET）Quotes delayed by 15 min

383.69MMarket Cap

--P/E TTM



Immuron Ltd

1.640

-0.020-1.20%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Immuron Ltd

Currency: USD Updated: 2025-10-27

Key Insights

Its valuation is considered fairly valued,and institutional recognition is low. Over the past 30 days, multiple analysts have rated the company as a . The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Immuron Ltd's Score

Industry at a Glance

Industry Ranking

141 / 173

Overall Ranking

623 / 4682

Industry

Pharmaceuticals

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 1 analysts

Buy

Current Rating

4.000

Target Price

+143.90%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Immuron Ltd Highlights

StrengthsRisks

Immuron Limited is an Australia-based biopharmaceutical company focused on developing and commercializing orally delivered targeted polyclonal antibodies for the treatment of infectious diseases. It operates through two segments: Research and development (R&D), and Hyperimmune products. The R&D segment is focused on R&D projects performed in Australia and the United States. Hyperimmune products segment is engaged in Travelan and Protectyn activities which occur predominantly in Australia, the United States and Canada. Its flagship products consist of Travelan and Protectyn. Travelan is an orally administered passive immunotherapy that prophylactically reduces the likelihood of contracting traveler’s diarrhea and is sold in pharmacies throughout Australia. Protectyn is sold online and in health practitioner clinics and is marketed as an immune supplement to help maintain a healthy digestive function and liver. Its clinical programs include Travelan (IMM-124E), IMM-529, and CampETEC.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 300.81% year-on-year.

Growing

The company is in a growing phase, with the latest annual income totaling USD 11.16M.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 11.16M.

Fairly Valued

The company’s latest PE is -63.77, at a medium 3-year percentile range.

Institutional Selling

The latest institutional holdings are 23.04K shares, decreasing 45.77% quarter-over-quarter.

Financial Health

Currency: USD Updated: 2025-10-27

There is no financial score for this company; the Pharmaceuticals industry's average is 7.77. Its latest quarterly revenue reached 6.44M, representing a year-over-year increase of 77.46%, while its net profit experienced a year-over-year increase of 25.64%.

Score

Industry at a Glance

Previous score

0.00

Change



Financials



Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings



Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency



Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential



Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns



Key Metrics

Free cash flow

No Data

Immuron Ltd's Company Valuation

Currency: USD Updated: 2025-10-27

There is no valuation score for this company; the Pharmaceuticals industry's average is 7.19. Its current P/E ratio is -63.77, which is -100.00% below the recent high of 0.00 and -121.37% above the recent low of -141.17.

Score

Industry at a Glance

Previous score

0.00

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 141/173

No Data

Earnings Forecast

Currency: USD Updated: 2025-10-27

There is no earnings forecast score for this company; the Pharmaceuticals industry's average is 7.78. The average price target for Immuron Ltd is 5.00, with a high of 5.00 and a low of 5.00.

Score

Industry at a Glance

Previous score

0.00

Change

Support & Resistance

No Data

Analyst Rating

Based on 1 analysts

Buy

Current Rating

4.000

Target Price

+143.90%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

169

Total

Median

Average

Company name

Ratings

Analysts

Immuron Ltd

IMRN

Biogen Inc

BIIB

Amgen Inc

AMGN

Vertex Pharmaceuticals Inc

VRTX

Eli Lilly and Co

LLY

AbbVie Inc

ABBV

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-10-27

The company’s current price momentum score is 7.24, which is higher than the Pharmaceuticals industry's average of 7.05. Sideways: Currently, the stock price is trading between the resistance level at 2.44 and the support level at 1.92, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

7.08

Change

0.16

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(4)

Neutral(2)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

-0.144

Sell

RSI(14)

36.431

Neutral

STOCH(KDJ)(9,3,3)

25.935

Neutral

ATR(14)

0.172

High Vlolatility

CCI(14)

-115.259

Sell

Williams %R

76.344

Sell

TRIX(12,20)

-0.470

Sell

StochRSI(14)

43.766

Buy

Moving Average

Sell(6)

Neutral(0)

Buy(0)

Indicators

Value

Direction

MA5

1.708

Sell

MA10

1.896

Sell

MA20

2.035

Sell

MA50

1.982

Sell

MA100

1.868

Sell

MA200

1.854

Sell

Institutional Confidence

Currency: USD Updated: 2025-10-27

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

UBS Financial Services, Inc.

16.30K

Rhumbline Advisers Ltd. Partnership

5.94K

Morgan Stanley & Co. LLC

700.00

BNP Paribas Securities Corp. North America

100.00

SBI Securities Co., Ltd.

10.00

Wells Fargo Advisors

-100.00%

HRT Financial LP

-100.00%

Morgan Stanley Smith Barney LLC

-100.00%

Two Sigma Investments, LP

-100.00%

Global Wealth Management Investment Advisory, Inc.

-100.00%

Risk Assessment

Currency: USD Updated: 2025-10-27

There is no risk assessment score for the company; the Pharmaceuticals industry's average is 5.11. The company's beta value is 0.63. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.